Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Pircher

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Oncology Research and Treatment|March 22, 2018
Anti-Angiogenics: Their Value in Colorectal Cancer TherapyAndreas Seeber, Eberhard Gunsilius, Günther Gastl, et al.
Memo|January 1, 2019
ASCO 2018 NSCLC highlights-combination therapy is keyGabriele Gamerith, Florian Kocher, Jakob Rudzki, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2010
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patientsAndreas Pircher, Ferdinand Ploner, Helmut Popper, et al.
Frontiers in Cell and Developmental Biology|September 25, 2020
Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future PerspectivesLaurenz Nagl, Lena Horvath, Andreas Pircher, et al.
Expert Opinion on Therapeutic Targets|January 14, 2017
Vessel pruning or healing: endothelial metabolism as a novel target?Anna Rita Cantelmo, Andreas Pircher, Joanna Kalucka, et al.
BMJ Case Reports|July 5, 2012
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantationAndreas Pircher, Eva Maria Gassner, Michael Steurer, et al.
Frontiers in Cell and Developmental Biology|January 20, 2021
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel InhibitionSophia Daum, Hannes Hagen, Erin Naismith, et al.
In Vivo (Athens, Greece)|May 13, 2014
Paraneoplastic phenomena and diagnostic challenges in angioimmunoblastic T-cell lymphoma (AITL): report of two cases and review of the literatureAndreas Pircher, Irmgard Verdorfer, Andrea Brunner, et al.
Oncology|August 26, 2015
NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL StudyFlorian Kocher, Fabian Lunger, Andreas Pircher, et al.
Molecular Cancer|September 12, 2020
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlookLena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Oncology Research and Treatment|March 22, 2018
Anti-Angiogenics: Their Value in Colorectal Cancer TherapyAndreas Seeber, Eberhard Gunsilius, Günther Gastl, et al.
Memo|January 1, 2019
ASCO 2018 NSCLC highlights-combination therapy is keyGabriele Gamerith, Florian Kocher, Jakob Rudzki, et al.
Lung Cancer (Amsterdam, Netherlands)|February 20, 2010
Rationale of a relaunch of gefitinib in Caucasian non-small cell lung cancer patientsAndreas Pircher, Ferdinand Ploner, Helmut Popper, et al.
Frontiers in Cell and Developmental Biology|September 25, 2020
Tumor Endothelial Cells (TECs) as Potential Immune Directors of the Tumor Microenvironment - New Findings and Future PerspectivesLaurenz Nagl, Lena Horvath, Andreas Pircher, et al.
Expert Opinion on Therapeutic Targets|January 14, 2017
Vessel pruning or healing: endothelial metabolism as a novel target?Anna Rita Cantelmo, Andreas Pircher, Joanna Kalucka, et al.
BMJ Case Reports|July 5, 2012
Durable complete remission in a patient with recurrent DLBCL receiving rituximab monotherapy after high-dose chemotherapy and autologous stem cell transplantationAndreas Pircher, Eva Maria Gassner, Michael Steurer, et al.
Frontiers in Cell and Developmental Biology|January 20, 2021
The Role of Anti-angiogenesis in the Treatment Landscape of Non-small Cell Lung Cancer - New Combinational Approaches and Strategies of Neovessel InhibitionSophia Daum, Hannes Hagen, Erin Naismith, et al.
In Vivo (Athens, Greece)|May 13, 2014
Paraneoplastic phenomena and diagnostic challenges in angioimmunoblastic T-cell lymphoma (AITL): report of two cases and review of the literatureAndreas Pircher, Irmgard Verdorfer, Andrea Brunner, et al.
Oncology|August 26, 2015
NSCLC without Antineoplastic Treatment: Incidence, Characteristics, and Outcome as Outlined in the TYROL StudyFlorian Kocher, Fabian Lunger, Andreas Pircher, et al.
Molecular Cancer|September 12, 2020
Overcoming immunotherapy resistance in non-small cell lung cancer (NSCLC) - novel approaches and future outlookLena Horvath, Bernard Thienpont, Liyun Zhao, et al.
Pageof 10